February 2, 2016 Seikagaku Corporation (Securities Code: 4548)
Seikagaku Corporation (Tokyo) today announced that it has decided to discontinue development of SI-657, an additional indication of enthesopathy for the joint function improving agent ARTZ .
SI-657 was being developed jointly with Kaken Pharmaceutical Co., Ltd. (“Kaken Pharmaceutical”), the sales partner of ARTZ in Japan. Because SI-657 didn’t have clear and enough data to exhibit the expected efficacy in the results of a Phase III clinical trial in Japan, Kaken Pharmaceutical and Seikagaku have agreed to discontinue development for the additional indication of enthesopathy, following careful consideration of future development policy.
Increasing added product value of ARTZ, Seikagaku will continue to focus its research and development on glycoscience and engage in efficient new drug development with GAGs (glycosaminoglycans) as target substances, and for orthopedic diseases, ophthalmic diseases, and immune and allergic diseases as target diseases.
There will be no revision in the forecasts of consolidated results for the fiscal 2015 due to this matter.